Drug Trial Radar · NCT07916883
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 18, 2026
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center
- First posted
- Nov 4, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the feasibility of imaging atherosclerosis by 64Cu-NODAGA-CANF PET-MR in a pilot study of patients with asymptomatic carotid artery stenosis (ACAS). The main question it aims to answer is: Can 64Cu-NODAGA-CANF PET detect carotid atherosclerosis in patients with ACAS? Uptake of 64Cu-NODAGA-CANF as measured by PET-MR will also be correlated to anatomic features of plaque on MRI, outcomes for patients treated with optimal medical therapy (OMT) alone or OMT and carotid endarterectomy (CEA) surgery, and tissue measurements for patients undergoing CEA surgery. The ability of 64Cu-NODAGA-CANF to risk stratify ACAS patients treated with OMT alone with respect to patient outcomes will be determined. Participants will * Receive a single intravenous (IV) administration of 64Cu-NODAGA-CANF followed by dynamic PET-MR imaging for up to 60 minutes and a second optional scan between 1-4 hours post-injection. * Undergo physical examinations, vital sign measurements, and blood and urine collection for clinical laboratory tests. * Undergo standard of care treatment with either OMT alone or OMT and CEA surgery. * Be evaluated with phone interviews 48-72 hours (2-3 days) after discharge and every 3 months (+/- 5 days) to assess for ipsilateral ischemic cerebrovascular event (transient ischemic attack (TIA), stroke) or remote ipsilateral carotid intervention.
Conditions
- Carotid Atherosclerosis
- Carotid Artery Stenosis Asymptomatic
- Asymptomatic Carotid Artery Stenosis
Interventions
64Cu-NODAGA-CANFDrug
Patients will receive a single intravenous (IV) injection of 8-10 mCi of 64Cu-NODAGA-CANF for PET-MR imaging at the imaging visit.
Optimal Medical Therapy (OMT)Drug
Patients will receive optimal medical therapy (OMT) as part of their standard of care treatment.
Carotid Endarterectomy (CEA) surgeryProcedure
Patients will undergo carotid endarterectomy (CEA) surgery as part of their standard of care treatment. The plaque specimen will be collected during surgery for ex vivo tissue measurements.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of 64Cu-NODAGA-CANF PET SUV (Standardized Uptake Value) between the atherosclerosis of the target diseased carotid artery and the non-diseased contralateral carotid artery or non-diseased vertebral arteryTime frame: Up to 4 hours post-injection of 64Cu-NODAGA-CANF
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cedars Sinai Medical Center
Los Angeles, California · Not yet recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.